May 27, 2020

Personal Protective Equipment Eases Fears During Period of G

Bizclik Editor
9 min

NEW YORK, May 26, 2020 /PRNewswire/ -- Infectious diseases such as Ebola, Influenza, Zika, MERS and the recent pandemic that is still spreading, cause enormous loss of life and devastate economies around world. Many factors influence the spread of such diseases, like globalization and associated travel and migration, the increasing population and suburban crowded homes, climate change, poor public health infrastructure and misuse of antibiotics are all, in part, responsible for the increase in severity of infectious disease. As the viral pandemic continues to ravage countries, so too does the world's collective uncertainty regarding when and how quickly society will return to normal. In the meantime, the importance and adoption of personal protective equipment (PPE) by the public has helped prevent even higher numbers of infected. PPEs are protective clothing, helmets, gloves, face shields, goggles, facemasks and/or respirators. When used properly, PPE acts as a barrier between infectious materials such as viral and bacterial contaminants and your skin, mouth, nose or eyes. Micron Waste Technologies Inc. (OTC: MICWD) (CSE: MWM), Co-Diagnostics, Inc. (NASDAQ: CODX), CytoDyn Inc. (OTC: CYDY), Aytu BioScience, Inc. (NASDAQ: AYTU), OPKO Health, Inc. (NASDAQ: OPK) 

Some PPEs are reviewed by the FDA before they can be legally sold in the United States. The manufacturers have to show they meet specific criteria for performance, labeling, and intended use to demonstrate substantial equivalence. The global personal protective equipment (PPE) market was valued at USD 52.7 Billion in 2019 and is expected to reach USD 92.5 Billion by 2025 while growing at a CAGR of 8.7% during 2020-2025, according to VynZ Research. Developments have also been made in the testing segment, as diagnostic testing has improved over the course of the last two months. By test type, the rapid antigen test is likely to hold substantial market share in 2020. Antigen assays are also usually more cost-effective when compared to either molecular or culture techniques. Now, various companies from a vast field of industries, including biotechs, medical device manufacturers, tech conglomerates and others have all made various announcements of products or services related to the pandemic, with testing kits playing a key role.

Micron Waste Technologies Inc. (OTC: MICWD) (CSE: MWM) and its 100% owned subsidiary Covid Technologies Inc., announced today breaking news that, "the world-wide community is achieving high levels of success in using face masks to prevent the spread of the COVID-19 virus.

About COVID Technologies Inc ( - In this time of crisis Covid Technologies Inc is preparing to deliver much needed PPE by provid-ing Canadian-made, high quality, vapour barrier technology (masks, protective garments), pro-tecting them from biological hazards, pathogens, and superbugs. 

Covid Technologies has established manufacturing capacity at its Delta, BC manufacturing fa-cility through the acquisition of mask making equipment, including the purchase from Asia of a FLK120 surgical mask making machine and over 5 tonnes of raw material for mask production. (All items prepaid and enroute for delivery to Covid facilities in Delta BC for early June 2020 Covid has paid for the ordered equipment from existing working capital and has approximately $2.5M additional cash and manufacturing assets to deploy towards facial mask making.

COVID Technologies Inc has secured an intermim MEDL Licencce (Medical Device Licence) and will begin production starting in June 2020 of:

  • Class 1 Protective 3ply Surgical masks equipment ASTM F2100 or F2101 guidelines. No licence or Health Canada clearance is required to manufacture these.

The Company also plans to manufacture N95 Respirators and is awaiting a licence from NIOSH (National Institute for Occupational Safety and Health (NIOSH) to be able to begin manufactur-ing these masks.

Face masks are not a substitute for physical distancing. The Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain the Covid-19 (or SARS-2 Coronavirus) at this time

The public is still advised to maintain at least six feet of distance from other people and stay home. Face masks are to be used when it is not possible to consistently maintain six feet of dis-tance from others or where work or businesses require them.

Micron Waste also announces that it has engaged Proactive Investors to provide investors relations services and written and video interview coverage of news releases and other corporate develop-ments. Proactive Investors is a financial news and events organization with bureaus in North America, the United Kingdom and Australia. Across all business lines, its worldwide client base numbers approx-imately 800 companies. Micron will compensate Proactive a sum total of $22,500 for a twelve month period to Proactivee."

Co-Diagnostics, Inc. (NASDAQ: CODX) announced earlier in May that its Logix Smart™ Coronavirus COVID-19 Test has been approved for sale in Mexico by the Mexican Department of Epidemiology ("InDRE") after InDRE successfully concluded an evaluation of the test's sensitivity and specificity and its non-reactivity with other respiratory viruses. InDRE, which is analogous to the U.S. Centers for Disease Control and Prevention (CDC), is required to evaluate any test to detect the disease before the test may gain clearance to be sold into the Mexican healthcare market. Co-Diagnostics also announced that CoSara, the Company's joint venture for manufacturing in India, expects to now begin filling orders following the successful evaluation of CoSara's Saragene™ COVID-19 RT-PCR test kit by the Indian Council of Medical Research (ICMR). The evaluation showed 100% sensitivity and 100% specificity without any cross reactivity with other respiratory viruses, and it has been cleared for sale to the Indian market.

CytoDyn Inc. (OTCQB: CYDY) announced last week it is offering comprehensive cytokine profiling (including RANTES levels) through its diagnostic partner company, IncellDx, to help physicians understand the pathogenesis of Childhood Inflammatory Disease Related to COVID-19. These laboratory tests are exploratory in nature and not intended for clinical decision making.

Recent reports in parts of the U.S. and Europe suggest a rare and potentially fatal inflammatory disease linked to the novel coronavirus is afflicting a small number of children. The condition resembles a rare childhood illness called Kawasaki disease, which has similar signs and symptoms and can lead to enlargement of blood vessels that in severe forms may cause heart damage. Nader Pourhassan, Ph.D., President and Chief Executive Officer of CytoDyn added, "We hope our comprehensive cytokine testing will help physicians gain a better understanding of the disease process and, in turn, explore the prospect for leronlimab to potentially provide a therapeutic benefit to children suffering from inflammatory illness related to COVID-19."

Aytu BioScience, Inc. (NASDAQ: AYTU) announced last month that it has received confirmation of export approval for product shipment by China's Ministry of Commerce for the Company's COVID-19 IgG/IgM Rapid Test. Josh Disbrow, Chief Executive Officer of Aytu BioScience, commented, "The backlog of medical products being exported from China created a shipment delay, but Aytu's next 500,000 rapid tests have now been cleared for shipment to the U.S. This export clearance from China, along with the additional supply we have secured through our new relationship with Biolidics, gives us great confidence in our supply chain and ability to provide these needed test kits to the U.S. medical community. Our shipments remain on track for delivery and, upon receipt, will be distributed to U.S. customers."

OPKO Health, Inc. (NASDAQ: OPK) announced back in April that beginning today it will offer antibody blood tests to detect an immune response after infection with the COVID-19 virus. Antibody testing and molecular diagnostic testing for COVID-19 are available to healthcare providers nationwide. In addition, under an agreement with New York State, BioReference will begin testing thousands of people per day for COVID-19 antibodies, starting today with MTA employees. BioReference began antibody testing last week with a focus on testing its employees. This week, BioReference launches COVID-19 antibody testing nationwide and is working expeditiously to be able to test 400,000 patients per day by mid-May.

Subscribe Now! Watch us report LIVE 

Follow us on Twitter for real time Financial News Updates: 

Follow and talk to us on Instagram: 

Facebook Like Us to receive live feeds: 

About, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, creates 100% unique original content. also provides financial news PR dissemination, branding, marketing and advertising for third parties for corporate news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.

Please Note: is not a financial advisory or advisor, investment advisor or broker-dealer and do not undertake any activities that would require such registration. The information provided on (the "site") is either original financial news or paid advertisements provided [exclusively] by our affiliates (sponsored content),, a financial news media and marketing firm enters into media buys or service agreements with the companies which are the subject to the articles posted on the Site or other editorials for advertising such companies. has not been compensated directly by any of the companies mentioned here in this editorial unless mentioned otherwise. We are not an independent news media provider and therefore do not represent or warrant that the information posted on the Site is accurate, unbiased or complete. receives fees for producing and presenting high quality and sophisticated content on along with other financial news PR media services. does not offer any personal opinions or bias commentary as we purely incorporate public market information along with financial and corporate news. only aggregates or regurgitates financial or corporate news through our unique financial newswire and media platform. For Micron Waste Technologies Inc. financial and corporate news dissemination, has been compensated five thousand dollars by the company. Our fees may be either a flat cash sum or negotiated number of securities of the companies featured on this editorial or site, or a combination thereof. The securities are commonly paid in segments, of which a portion is received upon engagement and the balance is paid on or near the conclusion of the engagement. will always disclose any compensation in securities or cash payments for financial news PR advertising. does not undertake to update any of the information on the editorial or Site or continue to post information about any companies the information contained herein is not intended to be used as the basis for investment decisions and should not be considered as investment advice or a recommendation. The information contained herein is not an offer or solicitation to buy, hold or sell any security., members and affiliates are not responsible for any gains or losses that result from the opinions expressed on this editorial or Site, company profiles, quotations or in other materials or presentations that it publishes electronically or in print. Investors accept full responsibility for any and all of their investment decisions based on their own independent research and evaluation of their own investment goals, risk tolerance, and financial condition. By accessing this editorial and website and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy, as may be amended from time to time. None of the content issued by constitutes a recommendation for any investor to purchase, hold or sell any particular security, pursue a particular investment strategy or that any security is suitable for any investor. This publication is provided by Each investor is solely responsible for determining whether a particular security or investment strategy is suitable based on their objectives, other securities holdings, financial situation needs, and tax status. You agree to consult with your investment advisor, tax and legal consultant before making any investment decisions. We make no representations as to the completeness, accuracy or timeless of the material provided. All materials are subject to change without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed. For our full disclaimer, disclosure and Terms of Use, please visit:

Media Contact:
[email protected] 


Cision View original content:


Share article

Subscribe to our Newsletter
Receive the latest updates and news
Exclusive preview